Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II-III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy

Radu Valeriu Toma; Zgura Anca; Oana Gabriela Trifănescu; Laurenția Nicoleta Galeș; Antonia Ruxandra Folea; Loredana Stanca; Liviu Bîlteanu; Rodica M. Anghel

doi:10.12659/MSM.941754

20 September 2023 : Clinical Research

Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II-III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy

Radu Valeriu Toma^{^A Study design/planning

^B Data collection/entry

^C Data analysis/statistics

^G Funds collection

" data-author="4365589">12ABCG}, Zgura Anca^1E, Oana Gabriela Trifănescu^{^A Study design/planning

" data-author="4365591">12A}, Laurenția Nicoleta Galeș^{^D Data interpretation

^*Corresponding author: [email protected]
^*Corresponding author: [email protected]
" data-author="4365592">12D*}, Antonia Ruxandra Folea^{^C Data analysis/statistics

^D Data interpretation

^E Preparation of manuscript

^F Literature analysis/search

" data-author="4365593">2CDEF}, Loredana Stanca^3B, Liviu Bîlteanu^{³Department of Preclinical Science, Faculty of Veterinary Medicine, University of Agronomic Sciences and Veterinary Medicine, Bucharest, Romania
⁴Laboratory of Molecular Nanotechnologies, National Institute for Research and Development in Microtechnologies, Voluntary, Romania

^A Study design/planning

^B Data collection/entry

^C Data analysis/statistics

^D Data interpretation

^E Preparation of manuscript

^F Literature analysis/search

" data-author="4365595">234ABCDEF}, Rodica M. Anghel^1A

DOI: 10.12659/MSM.941754

Med Sci Monit 2023; 29:e941754

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Supplementary Table 11 RR and OR calculation for the associations presented in Figure 2 of the manuscript between an echocardiographic outcome variable and the dosimetric predictor variables.

Notations	Explanation	Example
	Predictor or independent variable	dosimetric variables (i.e. maximum dose, mean dose and V25 for LAD and the maximum dose and V25 for the whole heart or LAD)
	Classical percentiles α=0.25, 0.33, 0.50, 0.67 and 0.75 of the predictor variable	The values of dosimetric variables’ percentiles can be found in .^{Table S8}
→ {0,1}	Outcome variable with two realizations	decrease in EF by 5% during treatment administration
= 0	A EF drop of at least 5% does not occur
= 1	A EF drop of at least 5% occurs
(.)	Probability of an event	P( = 0) probability that no EF drop of at least 5% occurred within our study group
(.\|.)	Conditional probability	probability that no EF drop of at least 5% occurred within our study group knowing that the condition is valid, i.e. the value of the dosimetric variable is greater or equal than its 0.75 percentile that can be found in^{Supplementary Table 8}

	The relative risk and the odds ratio corresponding to the association between the decrease of EF by at least 5% during the multimodal treatment (Y = 1) and a maximum LAD dose higher than the 0.75 percentile calculated in the study group (i.e. 46.9 Gy, see ) are written as follows:and^{Supplementary Table 8}

Back to the Article

Early Echocardiography and ECG Changes Following Radiotherapy in Patients with Stage II-III HER2-Positive Breast Cancer Treated with Anthracycline-Based Chemotherapy with or without Trastuzumab-Based Therapy

Your Privacy